IP Library Granted Patent US 11,951,168
Granted Patent B2
US 11,951,168 · App. 16/321,973 · Granted Apr 9, 2024

Composition containing buffer

Inventors: Yuichi Funase (Ashigarakami-gun, JP); Masahiro Kurokawa (Sammu, JP)
Assignee: PERSEUS PROTEOMICS INC.
A61K47/12A61K33/24A61K33/244A61K47/18A61K47/50A61K51/00A61K51/048A61K51/0482A61P35/00A61P35/02A61K9/0019A61K51/1241
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,951,168
App. No.
16/321,973
Granted
Apr 9, 2024
Kind
B2
Abstract

Provided is a composition containing a buffer to be used at the time of labeling of a chelated targeting agent with 90 Y, 153 Sm, 165 Dy, 165 Er, 166 Ho, or 177 Lu. At least one kind of buffer selected from the group consisting of benzoic acid, maleic acid, fumaric acid, succinic acid, and salts thereof is incorporated in a composition containing a chelated targeting agent.

Claims (16)

1. A method of producing a radioactive metal-labeled chelated targeting agent, the method comprising:

adding a radioactive metal selected from the group consisting of 90 Y, 153 Sm, 165 Dy, 165 Er, 166 Ho, and 177 Lu to a mixture of a chelated targeting agent selected from the group consisting of a low-molecular-weight compound, a peptide, a protein, an antibody, an antibody fragment, and a nucleic acid chelated with at least one member selected from the group consisting of

and at least one buffer selected from the group consisting of benzoic acid, maleic acid, and salts thereof to form a complex between the radioactive metal and the chelated targeting agent,

wherein a pH of a reaction liquid at the time of labelling of the chelated targeting agent with the radioactive metal is adjusted to fall within a range of the pKa value of the buffer plus or minus 1.5.

2. A method of producing a radioactive metal-labeled chelated targeting agent, the method comprising:

adding a radioactive metal selected from the group consisting of 90 Y, 153 Sm, 165 Dy, 165 Er, 166 Ho, and 177 Lu to a mixture of a chelated targeting agent selected from the group consisting of a low-molecular-weight compound, a peptide, a protein, an antibody, an antibody fragment, and a nucleic acid chelated with at least one member selected from the group consisting of:

and at least one compound selected from the group consisting of benzoic acid, maleic acid, a conjugate base of benzoic acid, a conjugate base of maleic acid, a mixture of benzoic acid and a conjugate base of benzoic acid, and a mixture of maleic acid and a conjugate base of maleic acid, to form a complex between the radioactive metal and the chelated targeting agent,

wherein a pH of a reaction liquid at the time of labelling of the chelated targeting agent with the radioactive metal is adjusted to fall within a range of the pKa value of the compound plus or minus 1.5.

3. The method of claim 1 , wherein the radioactive metal is selected from the group consisting of 90 Y and 177 Lu.

4. The method of claim 1 , wherein the chelate group comprises a chelate group having a DOTA structure selected from the group consisting of

and the targeting moiety is an anti-CDH3 antibody.

5. The method of claim 2 , wherein the radioactive metal is selected from the group consisting of 90 Y and 177 Lu.

6. The method of claim 2 , wherein the chelate group comprises a chelate group having a DOTA structure selected from the group consisting of

and the targeting moiety is an anti-CDH3 antibody.

7. The method of claim 1 , wherein the buffer is selected from the group consisting of benzoic acid, a conjugate base of benzoic acid, a mixture of benzoic acid and a conjugate base of benzoic acid.

8. The method of claim 2 , wherein the compound is selected from the group consisting of benzoic acid, a conjugate base of benzoic acid, a mixture of benzoic acid and a conjugate base of benzoic acid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2024
From: PDRADIOPHARMA INC.
To: PERSEUS PROTEOMICS INC.
Reel/Frame 066159/0734 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2022
From: FUJIFILM TOYAMA CHEMICAL CO., LTD.
To: PDRADIOPHARMA INC.
Reel/Frame 060350/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2019
From: FUNASE, YUICHI; KUROKAWA, MASAHIRO
To: FUJIFILM TOYAMA CHEMICAL CO., LTD.
Reel/Frame 048190/0905 →
Priority Claims (1)
JP 2016-161114 · Aug 19, 2016 · national
Continuity (1)
Related Publication 20190175736A1 · Jun 13, 2019